分類彙整:公司新聞

聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」

聯合生物製藥(股)公司(聯生藥)今日宣布,其愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」。

國家新創獎是國內生醫與健康領域研發成果的最高指標獎項,對於曾經獲頒國家新創獎後又持續精進創新且研發進程具體者,可申請續獎。UB-421於2015年首次獲頒國家新創獎,因後續研發成果具體而優異,從而榮獲今年度新創精進獎。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於 多重抗藥性HIV感染病患之臨床試驗協議

聯合生物製藥(股)公司(聯生藥)今日宣布,已和美國國家衛生研究院/過敏與傳染症研究所 (NIH/NIAID) 完成臨床試驗協議簽署,NIAID將贊助UB-421應用於治療多重藥抗藥性(Multiple Drug Resistance,MDR)HIV感染之臨床試驗。根據此協議,NIAID將負責提交Investigational New Drug Application (IND)並執行名為「A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection (UB-421結合優化背景抗逆轉錄病毒療法應用於多重抗藥HIV-1感染病患的單臂開放式2期試驗)」的臨床研究,聯生藥則負責提供研究藥物UB-421,以及執行藥物動力學和免疫原性分析試驗。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421

Taipei, Taiwan –November 25 2019 –United BioPharma (UBP) announced today the signing of a clinical trial agreement with NIH/NIAID (National Institute of Allergy and Infectious Diseases) for their sponsorship of a clinical trial with UB-421 for treatment of multi-drug resistant (MDR) HIV infection. NIAID will be responsible for the submission of an IND and execution of the trial entitled “A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection”. Under the agreement, UBP will provide the study drug, UB-421, and perform pharmacokinetic and immunogenicity assays. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

Mei Mei Hu — TIME 100 NEXT

Even with scientists as parents, it wasn’t always obvious that Mei Mei Hu would end up as the CEO of United Neuroscience, a company she co-founded in 2014 to find new ways to fight brain diseases like Alzheimer’s. She earned a law degree and joined a consulting firm before being lured back to science—experiences that she credits with giving her insights into solving complex problems in creative ways. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥單株抗體新藥 UB-221 獲美國 FDA 核准 在慢性自發性蕁麻疹患者進行臨床一期試驗

聯合生物製藥(股)公司(聯生藥)今日宣布,其新型抗IgE單株抗體藥物 UB-221 已獲得美國FDA 核准在標準一線藥物H1 抗組織胺治療無效的慢性自發性蕁麻疹(Chronic Spontaneous Urticaria,CSU) 病患進行臨床一期試驗。慢性蕁麻疹的患病率約為1.8%。慢性自發性蕁麻疹發生率則約0.5〜1%。三分之二的慢性蕁麻疹是自發性的, 20至40歲之間是發病高峰期。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria

Taipei, Taiwan, November 8th , 2019 — United BioPharma (UBP) announced today that they have received Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 1 clinical trial with a novel anti-IgE monoclonal antibody UB-221, in patients suffering from chronic spontaneous urticaria (CSU) that is not adequately controlled by standard first-line H1-antihistamine treatments. The lifetime prevalence of chronic urticaria is approximately 1.8%. Chronic spontaneous urticaria occurs in 0.5~1% of the population at any point in time. Two out of three cases of chronic urticaria are spontaneous, with its incidence peaking between 20 and 40 years of age . 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯亞藥(6562)終止興櫃買賣Q & A

公司終止興櫃股票買賣的原因是什麼?是否也會停止公開發行? 是否會到海外上市?
Ans:(1) 本公司因研發經費擴大、虧損屢增,董事會經審慎考慮後決議終止公司股票興櫃買賣。本公司將調整營運方向,持續完成增資,擴充自動化針劑生產線,以擴大製藥營收及獲利。同時加速新藥國際授權,並進行組織變革,健全財務結構。營收獲利改善後,待未來適當時機重新啟動在台灣的上市櫃規劃及申請作業。 (2) 現階段本公司並沒有停止公開發行或海外上市的計畫。 繼續閱讀

發表於 公司新聞, 生醫新知, 社會經濟 | 發表迴響

基於台灣新藥資本市場環境丕變 聯亞藥董事會決議終止興櫃交易 待完成增資並調整公司營運方向後重啟IPO計畫

本公司(聯亞藥業股份有限公司,股票代號:6562)為調整經營策略、加速藥品國際授權、並強化財務結構,於108年10月18日經第三屆第十一次董事會決議終止興櫃股票櫃檯買賣。本公司將正式向財團法人中華民國證券櫃檯買賣中心申請終止興櫃股票櫃檯買賣,後續將依「證券商營業處所買賣興櫃股票審查準則」相關規定,辦理相關事宜。實際終止登錄興櫃股票日期將依照財團法人中華民國證券櫃檯買賣中心之公告為準。 繼續閱讀

發表於 公司新聞, 生醫新知, 社會經濟 | 發表迴響

愛滋病「每日用藥」治療模式,可能因一篇台灣研究而改變

從愛滋病被發現至今,其治療方式亦與時俱進。現在,患者能透過服用數十種藥物結合的複合劑來控制病毒,以防人體免疫系統受到嚴重損害,進而導致更嚴重、往往致命的後果。

但要控制愛滋病需要時時保持警戒。只要少服用幾劑藥物就可能給予病毒產生抗藥性的機會,並使這樣的新病毒大量複製而充斥全身。

在一篇發表於《新英格蘭醫學雜誌》(New England Journal of Medicine)的研究中,來自台灣聯合生物製藥公司(United BioPharma)的研究人員傳來令人振奮的消息。他們發現似乎僅需要定期注射藥物,就能成功阻斷愛滋病毒,同時改變當前每天都得服用的用藥模式。連同此研究結果在內,已有越來越多研究認為愛滋患者或許能在不危及健康的情況下,在緊湊的服藥過程中喘口氣。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)

United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform capabilities. 繼續閱讀

發表於 Chang Yi Wang, 人物側寫, 公司新聞, 專家筆記, 王長怡, 王長怡博士演講, 生醫新知 | 發表迴響

英國著名PharmaBoardRoom媒體記者、訪問聯生藥董事長暨科學長 王長怡博士

聯合生物醫學集團 (UBI)是一致力於發現、開發和商業化用於慢性和感染性疾病的免疫治療藥品和疫苗,並熱衷於以平台技術提供科學驅動創新的公司。王長怡乃UBI旗下子公司之一的聯合生物製藥(United BioPharma,UBP)董事長兼首席科學長,而UBP正是她所創立的UBI集團的其中一企業。她談論了她令人驚豔的事業生涯,包括從1973年身為首位被美國洛克菲勒大學錄取的亞洲女性博士生,到有機緣受數位諾貝爾獎得主指導或與共事而被薰陶訓練,以及她如何利用研究和管理經驗在年輕時即創立UBI公司,及她在重要領域中堅持在公司內部建立自主生產技術背後的思維。 繼續閱讀

發表於 人物側寫, 公司新聞, 專家筆記, 王長怡, 王長怡博士演講, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

A vaccine for Alzheimer’s is on the verge of becoming a reality

For decades, research into Alzheimer’s has made slow progress, but now a mother and daughter team think they have finally found a solution – a vaccine that could inoculate potential 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

Is an Alzheimer’s Cure on the Horizon?

By the time I was old enough to ask my grandmother questions about her life, it was too late. All I had were skeletons of stories I heard from my mom. I knew that it had been difficult for my grandmother when her parents, Irish immigrants on the vaudeville circuit, left her behind to help care for her younger brother when they traveled. But who cared for her? I heard about how, after her parents became successful radio stars, she was once set up on a date with Frank Sinatra, but when he arrived, with my grandmother waiting to make an entrance, he used language she didn’t like, so she sent word that she wouldn’t be going. But what had he said? I knew that she and my grandfather divorced not long after my mom was born, and that my grandmother subsequently spent time in the hospital. But for what illness? When I’d ask her, she’d respond about the weather. And maybe this was because she didn’t want to talk about it. Or maybe she didn’t remember. For years, her body was well but her mind was dying. It was like watching the electric grid of a city shut off one neighborhood at a time, until almost every street was dark. 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

聯生藥治療單純皰疹病毒抗體新藥UB-621獲美國FDA核准 執行臨床2期復發型生殖器皰疹試驗

聯合生物製藥(股)公司(聯生藥)今日宣布,抗皰疹病毒單株抗體藥物UB-621已獲得美國FDA批准在由HSV-2感染所引起之復發型生殖器皰疹 (Recurrent Genital)患者族群上進行臨床第2期試驗: “A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 in Adults with Recurrent Genital HSV-2 Infection”。UB-621可透過和病毒(HSV-1和HSV-2) 外表包膜上gD 蛋白之靶點作高親和力結合的機制1,阻止病毒侵入宿主而抑制感染。 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響

United BioPharma Receives US FDA Approval for UB-621 Phase 2 Trial in Recurrent Genital Herpes Patients

Taipei, Taiwan, June 10th , 2019 — United BioPharma (UBP) announced the receipt of Investigational New Drug (IND) approval from the U.S. FDA to conduct a phase 2 clinical trial with UB-621 monoclonal antibody for recurrent genital infection caused by Herpes Simplex Virus, type II (HSV-2). UB-621 works to inhibit the infection through high-affinity binding to the same epitope on viral surface envelope gD protein on both type I (HSV-1) and type II (HSV-2) viruses.1 繼續閱讀

發表於 公司新聞, 生醫新知, 產業訊息, 社會經濟 | 發表迴響